Subtitle: Epigenetic NuRD Complex Targeting, Clinical Progress, and High-Purity Reagents for Oncology & Hemoglobinopathy Therapeutics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CHD4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CHD4 Recombinant Protein (ATPase Domain / Chromodomain) High purity (>95% by SDS-PAGE), Endotoxin <1.0 EU/μg. Sequence Verified. Optimized for biochemical assays. |
View CHD4 Products |
| Gene Delivery | CHD4 Promise-ORF / Lentivirus Full-length human CHD4 ORF in lentiviral vectors for stable cell line construction and target validation. |
View CHD4 Products |
| Benchmark Ab | Anti-CHD4 Recombinant Antibody High-affinity recombinant positive control antibody for Western Blot, IP, and ChIP assays. |
View CHD4 Products |
| Validator | CHD4 siRNA Set Target-specific siRNA pool for robust knockdown verification in functional assays. |
View CHD4 Products |
| Related Target A | HDAC1 Core catalytic component of the NuRD complex; co-targets for epigenetic transcriptional regulation. |
View HDAC1 Products |
| Related Target B | PARP1 Synergistic DNA damage repair target; CHD4 inhibition sensitizes BRCA-proficient cancers to PARP inhibitors. |
View PARP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ATPase domain activity screening | High-purity recombinant CHD4 ATPase domain expressed in insect cells/E. coli with strict sequence verification. |
| Selectivity screening against CHD family | Homolog panel proteins (CHD1, CHD3, CHD5) available with theoretical MW and purity verified by SDS-PAGE. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and positive control plasmids included. |
| False Positives | Validated siRNA sets included for phenotypic confirmation post-knockdown. |
Live CHD4 R&D Tracker
Epigenetic drug discovery moves rapidly. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CHD4 therapeutics is intensifying, with major players shifting focus from broad epigenetic modifiers to precise NuRD complex disruptors. CHD4 (Chromodomain-helicase-DNA-binding protein 4) acts as the catalytic core of the NuRD (Nucleosome Remodeling and Deacetylase) complex, making it a highly sought-after target in oncology and hematology. As first-generation therapies reach the clinic, the next wave of R&D is targeting selective small-molecule ATPase inhibitors, PROTAC-mediated degraders, and genetic therapies aimed at fetal hemoglobin (HbF) induction for sickle cell disease and beta-thalassemia.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Epigenetic Biotechs | Ovarian Cancer, Breast Cancer, Endometrial Cancer | ATPase Activity Assay (Need high-purity active ATPase domain proteins) |
| PROTAC Degraders | Targeted Protein Degradation (TPD) Pioneers | Hematological Malignancies, Solid Tumors | Binary/Ternary Complex Formation (Need high-purity full-length or domain-specific proteins) |
| Gene Modulation / RNAi | Gene Therapy Developers | Sickle Cell Disease, Beta-Thalassemia | Target Knockdown Verification (Need validated siRNA and Lentivirus tools) |